ARTICLE | Clinical News
PhotoPoint SnET2 tin ethyl etiopurpurin: Continued Phase III trials
January 29, 2001 8:00 AM UTC
Miravant Medical Technologies Inc. (MRVT), Santa Barbara, Calif. Product: PhotoPoint SnET2 tin ethyl etiopurpurin Business: Ophthalmic Therapeutic category: Cytotoxic Target: Retinal vessels Descripti...